Abstract: An electronic device presents a virtual behavior of a participant in a Metaverse. The electronic device determines a context of the Metaverse including the people meeting with the participant. The electronic device determines a real-world behavior of the participant while immersed in the Metaverse. The electronic device generates virtual behavior of the participant based on the context of the Metaverse and the real-world behavior of the participant while immersed in the Metaverse. The electronic device renders an avatar of the participant having the virtual behavior of the participant.

Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Abstract: The present disclosure provides a composition. In an embodiment, a catalyst composition is provided and includes from 85 mol % to 95 mol % iron metal, and from 15 mol % to 5 mol % indium metal, wherein mol % is based on total moles of iron metal and indium metal. Also provided is a process of contacting, under reaction conditions, a gaseous mixture of carbon monoxide, hydrogen and optionally water with the catalyst composition. The process includes forming a reaction product composed of light olefins.

Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Abstract: The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Abstract: Methods of making a Ce0.6Zr0.4O2 supported NiMg catalyst extrudate are provided. In some aspects, the methods include preparing a ceria-zirconia solution comprising Ce(NO3)3.6H2O, ZrO(NO3)2xH2O, and water; forming a precipitate; drying and calcining the precipitate to produce a Ce0.6Zr0.4O2; adding a nickel-magnesium solution to the Ce0.6Zr0.4O2 to produce the NiMg/Ce0.6Zr0.4O2; and drying and calcining a wet extrudate of the NiMg/Ce0.6Zr0.4O2 to produce the Ce0.6Zr0.4O2 supported NiMg catalyst extrudate. Ce0.6Zr0.4O2 supported NiMg catalyst extrudates made by the methods are also provided.

Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Abstract: In some embodiments, method for producing liquid fuel from landfill gas, the method including providing landfill gas to a tri-reformer, performing a tri-reforming process on the landfill gas within the tri-reformer to convert the landfill gas into synthesis gas, wherein the tri-reforming process combines carbon dioxide reforming, steam reforming, water-gas shifting, and methane oxidation and wherein the synthesis gas has a H2:CO ratio of approximately 2:1, providing the synthesis gas to a Fischer-Tropsch synthesis (FTS) reformer, and converting the synthesis gas into liquid fuel within the FTS reformer.

Abstract: In recent years, a great deal of attention has been drawn to the issue of water contamination, particularly in developing countries, where an inexpensive, effective method of reducing waterborne pathogens and contaminants is needed. Experiments performed with mucilage extracted from the Opuntia ficus-indica cactus show that this mucilage is an effective tool for clearing contaminants from water supplies, including the removal of Escherichia coli and Bacillus cereus bacteria, and the reduction of arsenic concentrations with very low mucilage concentrations (5 mg/L and 10 mg/L). Results for Bacillus and E. coli show settling to be complete in approximately five to ten minutes with removal rates of up to 97%, when CaCl2 is co-applied. Arsenic is removed at between 35% to 85% by increasing the contact time between the mucilage and the arsenic solutions depending on the pH and mucilage concentration.

Abstract: In some embodiments, a system for producing liquid fuel from landfill gas includes a tri-reformer that receives landfill gas and produces synthesis gas having a H2:CO ratio of approximately 2:1, and a Fischer-Tropsch synthesis (FTS) reformer that receives the synthesis gas from the tri-reformer and produces liquid fuel.

Abstract: In some embodiments, a system for producing liquid fuel from landfill gas includes a tri-reformer that receives landfill gas and produces synthesis gas having a H2:CO ratio of approximately 2:1, and a Fischer-Tropsch synthesis (FTS) reformer that receives the synthesis gas from the tri-reformer and produces liquid fuel.

Abstract: In one embodiment, liquid hydrocarbon fuels are produced in a single reactor using a hybrid catalyst system including a reforming catalyst, a Fischer-Tropsch synthesis (FTS) catalyst, and a porous material that spatially separates the reforming catalyst from the FTS catalyst.

Abstract: Arsenic is a poisonous metalloid which, because of its hydroscopic nature, is primarily transported through water. Most plant species, including the nopal cactus, produce a sticky substance called mucilage. Mucilage swells in water but is insoluble and can precipitate ions, bacteria and particles from aqueous solutions. The invention includes a method of separating particulates and heavy metals such as arsenic (As) from drinking water using natural flocculants obtained from cactus mucilage. The extraction techniques and the methodology for using the cactus mucilage obtain higher As removal than conventional methods, like aluminum sulfate precipitation.

Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8 and n are defined in the specification, methods for using said compounds, methods for making said compounds and pharmaceutical compositions containing said compounds.

Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.

Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.